Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intrathecal Pemetrexed for Recurrent Leptomeningeal Metastasis from NSCLC
NCT03101579Phase 1Completed
- Sponsor
- The First Hospital of Jilin University
- Start
- Mar 2017
- Primary completion
- Sep 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of pemetrexed in leptomeningeal metastases (LM), sponsored by The First Hospital of Jilin University. Primary endpoints: Incidence of severe adverse events at 2 months and Maximal tolerated dose at 2 months. Started Mar 2017; status: completed.
02
Drugs
pemetrexed
03
Conditions
leptomeningeal metastases (LM)
Beyond the preview
Go deeper on NCT03101579.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03101579.